Evidence map›Paper›PMID 40916717›Full record

ArticlePsychological medicine2025

Dopamine D

Franciska de Beer, Erik de Vries, Ben Wijnen, Marieke J H Begemann, Nico van Beveren, Nynke Boonstra, Shiral S Gangadin, Lieuwe de Haan, Iris M H Hamers, Wim Veling and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Comment on 'Dopamine DPsychological medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Franciska de Beerhttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.ORCID 0000-0002-0740-0969
Erik de Vrieshttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands.ORCID 0000-0002-6915-1590
Ben WijnenCentre of Economic Evaluations & Machine Learning, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.ORCID 0000-0001-7993-1905
Marieke J H Begemannhttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.ORCID 0000-0001-6448-2799
Nico van BeverenParnassia Group for Mental Health Care, The Hague, The Netherlands.
Nynke BoonstraDepartment of Healthcare, NHL Stenden University of Applied Sciences, Leeuwarden, The Netherlands.
Shiral S Gangadinhttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.ORCID 0000-0002-0084-8226
Lieuwe de HaanDepartment of Psychiatry, Amsterdam University Medical Centre - location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Iris M H Hamershttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.ORCID 0009-0007-0296-3969
Wim VelingUniversity of Groningen, University Medical Centre Groningen, Department of Psychiatry, Groningen, The Netherlands.ORCID 0000-0002-1364-9779
Sanne Koopshttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.
Iris E C Sommerhttps://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D

methodsRemitted FEP patients underwent two [

resultsOne week after discontinuation, D

conclusionsDiscontinuation of partial D

Indexed as

Antipsychotic AgentsCorpus StriatumDopamine D2 Receptor AntagonistsPsychotic DisordersReceptors, Dopamine D2Receptors, Dopamine D3AdultCase-Control StudiesFemaleHumansMalePositron-Emission TomographyRacloprideRecurrenceYoung AdultAntipsychotic AgentsDopamine D2 Receptor AntagonistsDRD2 protein, humanDRD3 protein, humanRacloprideReceptors, Dopamine D2Receptors, Dopamine D3antipsychotic discontinuationantipsychotic medicationdopamineFirst-episode psychosispositron emission tomographypsychotic relapse

Identifiers

PMID40916717
PMCPMC13040595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.